Imaging and bone marrow assessments improve minimal residual disease prediction in multiple myeloma

34Citations
Citations of this article
36Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The value of minimal residual disease (MRD) status by bone marrow and imaging analysis as independent prognostic factors has been well established in multiple myeloma (MM). Nevertheless data about their potential complementarity for a more accurate assessment are limited. With this aim, we retrospectively analyzed the prediction of outcome with the combination of PET-CT and MRD, assessed by multiparameter flow cytometry (MFC) in 103 patients with newly diagnosed MM. We confirmed the benefit in terms of progression-free survival (PFS), linked to the achievement of negativity by MFC (hazard ratio [HR] 0.53; 95% confidence interval [CI]: 0.28-0.98), and PET-CT (HR 0.18; 95% CI: 0.09-0.36) individually. By combining both techniques, patients who became MRD-/PET-, with a median of PFS 92 months, had significant prolonged median PFS (P

Cite

CITATION STYLE

APA

Alonso, R., Cedena, M. T., Gómez-Grande, A., Ríos, R., Moraleda, J. M., Cabañas, V., … Martínez-López, J. (2019). Imaging and bone marrow assessments improve minimal residual disease prediction in multiple myeloma. American Journal of Hematology, 94(8), 853–861. https://doi.org/10.1002/ajh.25507

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free